What is Zacks Research’s Estimate for PRE Q2 Earnings?

Prenetics Global Limited (NASDAQ:PRE) – Equities researchers at Zacks Research issued their Q2 2026 earnings estimates for Prenetics Global in a research note issued on Wednesday, June 10th. Zacks Research analyst B. Sorensen expects that the company will post earnings per share of ($0.16) for the quarter. The consensus estimate for Prenetics Global’s current full-year earnings is ($1.77) per share. Zacks Research also issued estimates for Prenetics Global’s Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at $0.02 EPS, FY2026 earnings at ($1.58) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at $0.20 EPS, Q3 2027 earnings at $0.50 EPS, Q4 2027 earnings at $0.66 EPS and FY2027 earnings at $1.56 EPS.

Several other equities research analysts have also issued reports on PRE. Lake Street Capital started coverage on shares of Prenetics Global in a research note on Monday, March 16th. They issued a “buy” rating and a $29.00 price target on the stock. Wall Street Zen lowered shares of Prenetics Global from a “buy” rating to a “hold” rating in a research note on Monday, February 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.33.

Prenetics Global Trading Up 7.5%

Shares of PRE stock opened at $20.69 on Friday. Prenetics Global has a 1 year low of $6.88 and a 1 year high of $23.63. The firm’s fifty day moving average price is $18.20 and its two-hundred day moving average price is $17.83. The firm has a market capitalization of $349.12 million, a P/E ratio of -4.52 and a beta of 0.24.

Prenetics Global declared that its Board of Directors has approved a share repurchase plan on Friday, March 6th that permits the company to repurchase $40.00 million in shares. This repurchase authorization permits the company to buy up to 15.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PRE. Aberdeen Group plc bought a new position in shares of Prenetics Global in the 3rd quarter valued at about $979,000. JPMorgan Chase & Co. bought a new position in shares of Prenetics Global in the 3rd quarter valued at about $65,000. UBS Group AG grew its position in shares of Prenetics Global by 581.9% in the 3rd quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after acquiring an additional 39,733 shares during the period. Stevens Capital Partners grew its position in shares of Prenetics Global by 4.7% in the 4th quarter. Stevens Capital Partners now owns 18,207 shares of the company’s stock valued at $287,000 after acquiring an additional 825 shares during the period. Finally, Kingsview Wealth Management LLC bought a new position in shares of Prenetics Global in the 4th quarter valued at about $172,000. Institutional investors own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.